Drug Profile
Emilimogene sigulactibac - Ilya Pharma
Alternative Names: ILP-100Latest Information Update: 07 Jun 2023
Price :
$50
*
At a glance
- Originator Ilya Pharma
- Class Bacteria; Gene therapies; Skin disorder therapies
- Mechanism of Action Collagen modulators; Immunomodulators; Protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Wounds
- Preclinical Colitis
Most Recent Events
- 31 May 2023 Efficacy, pharmacodynamics and adverse events data from a phase I trial in Wounds released by Ilya Pharma
- 25 Apr 2023 Preclinical trials in Colitis in Sweden (PO) (Ilya Pharma pipeline, April 2023))
- 25 Apr 2023 Ilya Pharma pipeline plans a pre-IND Type B interaction meeting with the US FDA in Q1 2023 (Ilya Pharma pipeline, April 2023)